NIBERONOFER DAYCO: Open Payments
NPI 1598161234 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$637 in 31 payments from 12 companies in 2025. Trend: 2023 $425 · 2024 $494 · 2025 $637
Food & beverage: $637
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 7 | $146 |
| Amgen Inc. | 5 | $124 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $93 |
| PFIZER INC. | 2 | $51 |
| AstraZeneca Pharmaceuticals LP | 3 | $46 |
| GlaxoSmithKline, LLC. | 2 | $43 |
| Lilly USA, LLC | 2 | $35 |
| Astellas Pharma US Inc | 1 | $22 |
| ACADIA Pharmaceuticals Inc | 1 | $21 |
| Curonix LLC | 1 | $21 |
Products named: OTEZLA, Kerendia, Ozempic, Rybelsus, ELIQUIS, AIRSUPRA, MOUNJARO, TRELEGY ELLIPTA.
Industry payments across NV — which companies pay providers there.
